Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Exkivity
Mobocertinib is a small molecule tyrosine kinase inhibitor (TKI) specifically designed to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are a less common but clinically significant subtype of EGFR mutations found in non-small cell lung cancer (NSCLC). Mobocertinib acts by irreversibly binding to and inhibiting the activity of these mutant EGFR proteins, thereby blocking downstream signaling pathways that promote tumor growth and survival. It offers a targeted therapy option for patients with this specific genetic alteration.
Mobocertinib is used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Outcome:
Decreased Mobocertinib efficacy
Mechanism:
Reduced Mobocertinib plasma concentration
Outcome:
Potential decrease in Mobocertinib efficacy
Mechanism:
Moderate reduction in Mobocertinib plasma concentration
Outcome:
Slightly increased Mobocertinib absorption
Mechanism:
Enhanced solubility
Most likely new formulation: Combination therapy with other targeted agents or immunotherapy (Year: 2026, 60% confidence)
Based on clinical trial data and current usage trends, Mobocertinib is likely to remain a niche therapy specifically for EGFR exon 20 insertion-positive NSCLC, with potential expansion into earlier lines of treatment (70% confidence).
Antineoplastic, Tyrosine Kinase Inhibitor
Quinazoline Derivative